Morganella morganii

(aka Proteus morganii)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Morganella morganii, (aka Proteus morganii), is a Gram-negative, non-spore-forming, facultatively anaerobic, variably-motile, rod-shaped bacterium. It has been detected in at least 9 gut microbiome compilation studies or metastudies. The DNA G+C content is 50%. Morganella morganii is probably a common, although minor, coloniser of the gut. (Farmer1985; Ewing1962; Jensen1992; O'Hara2000; Shaw1955; Janda2005dBergey; Terekhov2018)



  • This organism has been recovered from human faeces, animals and clinical sources (trachea, blood, urine - CCUG). The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: human and animal pathogen). It is an opportunistic pathogen. A possible gut commensal. Robust growth can have negative consequences for gut health.
    • GENERAL CHARACTERISTICS (Farmer1985); (Ewing1962); (Jensen1992); (O'Hara2000); (Shaw1955); (Janda2005dBergey);
    Character Response
  • Substrates hydrolysed or digested:
  • urea;
  • 🌡
  • Temperature tolerance:
  • Grows optimally at 37℃.
  • H+
  • Acid from carbohydrates usually produced:
  • galactose; glucose; mannose;
  • ±
  • Strain-dependent acid from carbs:
  • glycerol;
  • Active enzymes:
  • catalase; lycine decarboxylase; ornithine decarboxylase; phenylalanine deaminase; urease;
    • SPECIAL FEATURES (Farmer1985); (Ewing1962); (Jensen1992); (O'Hara2000); (Shaw1955); (Janda2005dBergey);
    Character Response
  • ✓
  • Metabolites produced:
  • H₂S (variable); indole;
  • ✗
  • VP test:
  • not active
  • ±
  • ONPG test:
  • strain dependent
  • KCN growth:
  • growth observed
  • ✓
  • NO3➔NO2:
  • reduced
    • RESPONSE TO ANTIBIOTICS (Jensen1992); (O'Hara2000); (Janda2005dBergey); (Citron1997);
    Class Active Resistant
  • Penicillins:
  • aztreonam; ertapenem; imipenem; meropenem; piperacillin; piperacillin-tazobactam;
  • amoxicillin; amoxicillin-clavulanic acid; ampicillin;
  • Cephalosporins:
  • cefepime; cefotaxime; cefotetan; cefpirom; ceftazidime; ceftizoxime;
  • cefazolin; cefpodoxime; cefuroxime; cephalothin;
  • Macrolides:
  • azithromycin; clarithromycin;
  • Tetracyclines:
  • tetracycline; tigecycline;
  • Quinolines:
  • ciprofloxacin; levofloxacin; moxifloxacin; ofloxacin; trovafloxacin;
  • Aminoglycosides:
  • amikacin; gentamicin; tobramycin;
  • Heterocycles:
  • chloramphenicol;
  • metronidazole; nitrofurantoin; trimethoprim-sulfamethoxazole;
  • Miscellaneous antibiotics:
  • colistin; polymyxin B;

  • Müller, H. E. (1986). Occurrence and pathogenic role of Morganella-Proteus-Providencia group bacteria in human feces. Journal of Clinical Microbiology, 23(2), 404–405.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Gammaproteobacteria Order:  Enterobacterales Family:  Enterobacteriaceae Genus:  Morganella Alt. name:  Proteus morganii Gram stain:  neg O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  vr Morphology:  Rod
    Health:   Negative
    Source:  human faeces, animals and clinical sources (trachea, blood, urine - CCUG)
    DNA G+C(%):  50
    Opt. T:  37℃
    		Urea:  + Gelatin:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Galactose:  + Glucose:  + Mannose:  + Rhamnose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  neg Sucrose:  neg Trehalose:  neg Amygdalin:  neg Adonitol:  neg D-Arabitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  d Inositol:  neg Mannitol:  neg Sorbitol:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  neg Me-α-D-Mann:  neg Me-Xyloside:  neg Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Melibiose:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + Urease:  + Ac-β-glcamnd:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg ArgDH:  neg ArgDC:  neg LysDC:  d(+) OrnDC:  d(+) Phe deaminase:  + Lipase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  vr Indole:  +
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  R(>128)
    Augmentin:  R(MIC50): 16, MIC90: >128, RNG: (1–32)
    ampicillin:  Res
    aztreonam:  Sens
    piperacillin:  S(MIC50): -, MIC90: 8
    piper-taz:  S(≤1/≤1)
    ertapenem:  S(≤0.125/≤0.125)
    imipenem:  S(MIC50): 1, MIC90: 2, RNG: (0.125–2)
    meropenem:  S(MIC50): -, MIC90: 0.06
    cefazolin:  Res
    cefepime:  S(MIC50): -, MIC90: 0.06
    cefotaxime:  S(MIC50): -, MIC90: 1
    cefotetan:  S(MIC50): 0.5, MIC90: 2, RNG: (0.5–2)
    cefoxitin:  Var(MIC50): 8, MIC90: 16, RNG: (0.5–16)
    cefpirom:  S(MIC50): -, MIC90: 0.13
    cefpodoxime:  Res
    ceftazidime:  S(≤0.5/8)
    ceftizoxime:  S(MIC50): -, MIC90: 1
    cefuroxime:  Res
    cephalothin:  Res
    amikacin:  S(MIC50): ≤2, MIC90: ≤2, (≤1-8)
    gentamicin:  S(MIC50): 1, MIC90: 16, RNG: (0.5–64)
    tobramycin:  SensRNG: (0.25-2)
    azithromycin:  R(8->8)
    clarithromycin:  R(>100)
    ciprofloxacin:  S(MIC50): 0.03, MIC90: 0.25, RNG: (0.015–0.5)
    levofloxacin:  S(MIC50): 0.03, MIC90: 1, RNG: (0.015–1)
    moxifloxacin:  S(≤0.25/2)
    ofloxacin:  S(MIC50): 0.06, MIC90: 2, RNG: (0.015–2)
    trovafloxacin:  S(MIC50): 0.015, MIC90: 0.25, RNG: (0.015–0.25)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  Var(MIC50): 0.25->16), MIC90: Var(0.25->16
    minocycline:  Var(MIC50): 2->8), MIC90: Var(2->8
    tetracycline:  Sens
    tigecycline:  SensRNG: (1-8)
    chloramphenicol:  Sens
    metronidazole:  R(>200)
    nitrofurantoin:  Res
    SXT:  Res
    colistin:  Res
    polymyxin_B:  Res

    References

    SPECIFIC REFERENCES FOR MORGANELLA MORGANII
  • Farmer1985 - Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens.
  • Ewing1962 - The tribe Proteeae: its nomenclature and taxonomy.
  • Jensen1992 - Recognition of Morganella Subspecies, with Proposal of Morganella morganii subsp. morganii subsp. nov. and Morganella morganii subsp. sibonii subsp. nov.
  • O'Hara2000 - Classification, Identification, and Clinical Significance of Proteus, Providencia and Morganella.
  • Shaw1955 - Biochemical Classification of Proteus and Providence Cultures.
  • Janda2005dBergey - Bergey's manual of systematic bacteriology. Vol. 2, The Gammaproteobacteria Part B. Family Enterobacteriaceae, Genus XXI. Morganella
  • Terekhov2018 - Ultrahigh-throughput functional profiling of microbiota communities.
  • Citron1997 - Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR MORGANELLA MORGANII
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Finegold1974 - Effect of diet on human fecal flora: comparison of Japanese and American diets
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Li2019b - Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Woodmansey2004 - Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................
    • GENERAL REFERENCES FOR MORGANELLA MORGANII
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
    • Added: April 08, 2021